Floatz logo

Ponatinib

Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

Ariad PharmaceuticalsSmall moleculePhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) cohort.

Asset / SponsorPhaseRating
Gleevec/Glivec
Novartis Pharmaceuticals
Phase 1CC

Same molecule, other indications

Ponatinib is also rated in:

chronic myeloid leukemiaDormant
BB
Indicative ·
66 / 100
View asset →
B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)Dormant
BB
Indicative ·
65 / 100
View asset →
blast phase chronic myelogenous leukemia, BCR-ABL1 positiveDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →